Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 18/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5947980 | 0.89 | EPHX2 (0.67) | EPHX2CYP2C9CYP2C19CYP2J2SLC6A3 | |
| SCHEMBL5948066 | 0.88 | EPHX2 (0.66) | EPHX2CYP2C9CYP2C19CYP2J2SLC6A3 | |
| SCHEMBL5948059 | 0.88 | EPHX2 (0.66) | EPHX2CYP2C9CYP2C19CYP2J2SLC6A3 | |
| SCHEMBL5948178 | 0.84 | EPHX2 (0.63) | EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL5947741 | 0.84 | EPHX2 (0.75) | EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL5947660 | 0.84 | EPHX2 (0.76) | EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL5947879 | 0.83 | EPHX2 (0.60) | EPHX2CYP2C9CYP2C19CYP2J2SLC6A3 | |
| SCHEMBL5947835 | 0.83 | EPHX2 (0.60) | EPHX2CYP2C9CYP2C19CYP2J2SLC6A3 | |
| SCHEMBL5947658 | 0.82 | EPHX2 (1.00) | EPHX2CYP2C9CYP2C19CYP2J2SLC6A3 | |
| SCHEMBL5947822 | 0.82 | EPHX2 (0.59) | EPHX2CYP2C9CYP2C19CYP2J2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885697-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-13 | — | — | EP | disclosed |
| US-20060276515-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-07 | — | — | US | disclosed |
| WO-2006121719-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276515-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885CYP2C9 477/4885CYP2C19 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.